Anthera receives Cystic Fibrosis Foundation Therapeutics award to develop Sollpura

Anthera Pharmaceuticals has received funding worth up to USD 3 million from Cystic Fibrosis Foundation Therapeutics to support development of Sollpura(TM) (liprotamase), a mixture of non-porcine lipase, protease and amylase enzymes for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) and other diseases.

Anthera plans to initiate the phase III trial SOLUTION in the third quarter of 2015.The open-label study will recruit approximately 126 patients aged 7 years and older with CF-associated EPI and will administer oral liprotamase or porcine enteric-coated pancreatic enzymes (ClinicalTrials.gov Identifier NCT02279498). The primary endpoint measure is change in coefficient of fat absorption from baseline to week 8 (Anthera Pharmaceuticals News Release; ClinicalTrials.gov Web site).